"Calcium Channel Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
| Descriptor ID |
D002120
|
| MeSH Number(s) |
D27.505.519.562.124 D27.505.954.411.793.205
|
| Concept/Terms |
Calcium Channel Agonists- Calcium Channel Agonists
- Agonists, Calcium Channel
- Channel Agonists, Calcium
- Calcium Channel Activators
- Activators, Calcium Channel
- Channel Activators, Calcium
- Calcium Channel Agonist
- Agonist, Calcium Channel
- Channel Agonist, Calcium
|
Below are MeSH descriptors whose meaning is more general than "Calcium Channel Agonists".
Below are MeSH descriptors whose meaning is more specific than "Calcium Channel Agonists".
This graph shows the total number of publications written about "Calcium Channel Agonists" by people in this website by year, and whether "Calcium Channel Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Calcium Channel Agonists" by people in Profiles.
-
Wu M, White HV, Boehm BA, Meriney CJ, Kerrigan K, Frasso M, Liang M, Gotway EM, Wilcox MR, Johnson JW, Wipf P, Meriney SD. New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease. Neuropharmacology. 2018 03 15; 131:176-189.
-
Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Belardinelli L, Antzelevitch C. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm. 2007 May; 4(5):638-47.
-
Bergh JJ, Shao Y, Puente E, Duncan RL, Farach-Carson MC. Osteoblast Ca(2+) permeability and voltage-sensitive Ca(2+) channel expression is temporally regulated by 1,25-dihydroxyvitamin D(3). Am J Physiol Cell Physiol. 2006 Mar; 290(3):C822-31.
-
Sakarcan A. Chronic interstitial nephritis in two siblings. J S C Med Assoc. 2003 Oct; 99(10):305-6.
-
Yi GH, Burkhoff D, Zhang H, Zhu SM, Zwas D, Wang J. Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug; 286(2):760-6.
-
Garcia MC, Sanchez JA, Sharma VK, Sheu SS. Extracellular heparin inhibits Ca2+ transients and contraction in mammalian cardiac myocytes. Pflugers Arch. 1995 Nov; 431(1):84-90.